Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

January 31, 2025

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

February 23, 2024

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 08, 2021

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

December 30, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.